AC
MIRM icon

Aristeia Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Aristeia Capital’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.55M Buy
+64,475
New +$6.47M 0.1% 139

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aristeia Capital's MIRM Position: Q2 2026 in Review

Aristeia Capital opened a new position in Mirum Pharmaceuticals (MIRM) in Q2 2026: 64,475 shares worth $7.55M. The stake represents 0.1% of the portfolio and ranks #139 among its holdings.

327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Aristeia Capital held 64,475 shares of Mirum Pharmaceuticals worth $7.55M as of Q2 2026.
  • Mirum Pharmaceuticals was a new Aristeia Capital position in Q2 2026.
  • Mirum Pharmaceuticals made up 0.1% of Aristeia Capital's portfolio in Q2 2026, its #139 holding.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.